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ABSTRACT
The therapy of psoriatic arthritis (PsA) has
blossomed in the past decade. Inhibition of
tumor necrosis factor (TNF) has been at the fore
of this approach and has paved the way for the
investigation of many other potential pro-
inflammatory and signaling pathways. Most of
the initial studies of TNF inhibitors in PsA have
been conducted in specific populations, largely
focusing on those with established, peripheral
joint disease. That said, in excess of 10 years’
worth of real world clinical experience has led
to increased confidence in the wider use of
these agents. We are now faced with an exciting
time of discovery of many new molecules; these
not only include new, large protein biological
agents, but also smaller synthetic chemical
molecules, many of which can be
administered orally. Those currently under
development are discussed within this article.
Whilst there is scarce data about their real world
efficacy and safety profile, it is evident that the
therapeutic armamentarium for treating PsA
will greatly increase in the foreseeable future
and this is anticipated to improve patient
outcomes.
Keywords: Biologics; Disease modifying;
Molecule therapy; Psoriatic arthritis; Tumor
necrosis factor
INTRODUCTION
The optimal management of psoriatic arthritis
(PsA) entails the adequate suppression of
aberrant inflammatory processes that give rise
to the clinical PsA phenotype of joint stiffness,
pain, tenderness, and swelling. Categorized as
one of the seronegative spondyloarthropathies,
PsA can manifest as enthesitis, dactylitis,
synovitis, arthritis, and/or axial inflammation,
either in isolation or in any combination,
although animal models and clinical studies
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suggest that enthesitis may be the primary
lesion [1, 2]. The magnitude and chronicity of
psoriatic joint disease and the consequential
physical and financial burden, has, in recent
years, prioritized PsA on the research agenda [3].
Compared to rheumatoid arthritis (RA), the
optimal management of PsA still lags behind
considerably. Prior to the advent of biological
therapy for RA, disease-modifying anti-
rheumatic drugs (DMARDs; methotrexate or
sulfasalazine), were most well established
option, initially as monotherapy and then in
combination as required. The superior efficacy
of the biological agents, often anchored to
methotrexate therapy, are well established in
preventing joint damage and minimizing long-
term disability in RA [4–6].
However, for a number of reasons, making
progress in the therapeutic field for PsA has
been more complicated. Historically, PsA was
viewed as a less prevalent or severe disease. In
addition, it is considerably more heterogeneous
in its evolution and manifestations compared to
RA. To date, a reliable serum biomarker, such as
the anti-citrullinated protein antibody in RA,
does not exist for psoriatic joint disease
detection, and this is likely to have negatively
impacted on the generation of good-quality,
robust clinical trials for PsA. Whilst conventional
DMARDs have been employed as the mainstay of
PsA therapy for decades, there is a surprising
paucity of data to support their clinical efficacy,
with clinical experience generally taking
precedence over hard evidence. In addition, the
majority of trials in PsA have focused on the
treatment of peripheral arthritis in polyarticular
disease [7], and have largely ignored those
patients with primarily axial disease and other
subgroups including oligoarthritis.
The current British Society of Rheumatology
guidelines for the treatment of PsA were
published in 2005, when anti-TNF therapy was
not widely available [8]. Only one TNF inhibitor
was licensed for active PsA in the UK at the time
of publication (etanercept), and only one other
anti-TNF therapy demonstrated evidence in PsA
(infliximab). There are now four TNF inhibitors
with proven efficacy in PsA, established by
large, good-quality clinical trials, and a
number of novel compounds in development
which if prove to be safe, may translate into
promising additions to the biological
armamentarium against PsA [9–13]. This
article assimilates all of the relevant data
concerning both old and new biologic
molecules, and provides an evidence-based
review of the current and emerging
therapeutic options for PsA. However, rather
than systematically describe and appraise each
clinical study in detail, the pertinent
commonalities shall be summarized, and
relevant differences highlighted. At the current
time, patients within the UK must of course
fulfill the criteria for biological therapy as
stipulated by the National Institute for Health
and Clinical Excellence (NICE); that is, they
must have failed to improve on or tolerate first-
line, disease-modifying agents including
methotrexate, leflunomide, and sulfasalazine,
either alone or in combination.
ANTI-TNF AGENTS IN PSORIATIC
ARTHRITIS
Many pro-inflammatory cytokines have been
identified in the pathogenesis of PsA, but
amongst these, TNF-alpha exerts a key pro-
inflammatory role [14]. Increased levels of TNF-
alpha have been observed in skin, synovial
fluid, and synovial tissue from patients with
PsA [15] and allelic polymorphisms in the
promoter region for TNF-alpha have been
shown to correlate with certain aspects of the
disease [16]. TNF inhibitors have demonstrated
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efficacy in both the skin and joint
manifestations of psoriatic disease, as well as
preventing radiographic damage [9–13, 17]. In
the UK, four anti-TNF agents are licensed for the
treatment of PsA—infliximab, etanercept,
adalimumab, and golimumab. A fifth agent,
certolizumab, has also shown promising
efficacy in clinical trials [18, 19]. All trials
encompass PsA as a single entity, with no
primary endpoint data reporting results based
on the PsA subtype.
Almost universally, PsA studies have sought to
recruit patients with a predominantly peripheral
distribution of joint disease. However, it is
estimated that up to 40% of patients with PsA
will develop some disease within the axial
skeleton. Again, no specific data evaluating the
effects of TNF inhibitors at this site has been
forthcoming, and treatment guidance is based
entirely upon data extrapolated from studies into
other seronegative spondyloarthropathies,
particularly ankylosing spondylitis (AS) [20, 21].
In AS, TNF inhibitors are effective at suppressing
the clinical and imaging markers of inflammation
[22] and it is this effect that confers the likelihood
of benefit in axial PsA—the suppression of
associated bone formation (ankylosis) in AS has
yet to be determined [23].
The licensed TNF inhibitors each have a
distinct structure and target TNF-alpha in
slightly different ways, but essentially
potentiate the same overall anti-inflammatory
effect. Infliximab is a chimeric (mouse/human)
monoclonal IgG1 antibody, adalimumab and
golimumab are recombinant fully human IgG1
monoclonal antibodies, and etanercept is a
75 kDa IgG1 fusion protein—the former three
bind directly to both the circulating and
membrane-bound TNF-alpha molecule,
whereas etanercept reversibly binds soluble,
circulating TNF-alpha [24]. Despite these
structural differences, the different TNF
inhibitors exhibit comparable efficacy on the
joints [25, 26], although no direct head-to-head
trials have been conducted. The four licensed
agents have demonstrated efficacy at
12–16 weeks for PsA response criteria (PsARC)
response, American College of Rheumatology
(ACR) 20, 50, and 70 response, and Psoriasis
Area Severity Index (PASI) response [9–13, 27–
29]. Of note, the onset of clinical benefit of the
TNF receptor construct on etanercept has been
reported to be of slower onset in those with
more extensive skin disease than for the
monoclonal antibodies [9], although this was
challenged by the outcomes of the more recent
PRESTA trial [30]. Again, there are no direct
head-to-head comparisons available. This
slower onset of action is unlikely to pose a
significant problem in the rheumatologic arena,
where many PsA cases have a low PASI score
(and therefore less cosmetic urgency to respond
rapidly) and where current data leads us to
believe that no association between PASI score
and joint disease exists [31].
In addition to clinical features, subjective
improvements in the Health Assessment
Questionnaire (HAQ) are reported to be
greatest with adalimumab [10, 27] and
infliximab [11, 12] at 12 weeks, and with
adalimumab [10], etanercept [28], golimumab
[13] and infliximab [12] at 24 weeks, when
compared to non-TNF-alpha biologic agents,
such as ustekinumab (UST) [32] alefacept [33],
and placebo. Specifically looking at the TNF-
alpha inhibitors, a more recent indirect
comparison meta-analysis measured the
relative risks for the PsA response criteria
(PsARC) and mean differences for
improvements from baseline for the HAQ for
PsARC responders and non-responders.
Etanercept and infliximab yielded the largest
mean difference in HAQ score among PsARC
responders, while for non-responders,
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etanercept, infliximab and golimumab yielded
similar mean differences and adalimumab a
notably lower mean difference [34].
The key pathogenic importance of enthesitis
and dactylitis in PsA has been established [2, 35,
36], and the original studies into TNF inhibitors
suggested superiority of some agents (infliximab
[11, 12]) over others. In total, seven randomized
controlled trials have published data on
enthesitis and dactylitis as secondary
endpoints [10–13, 27, 32, 37]. In addition to
infliximab [11, 12], golimumab [13] (a second
generation agent licensed for PsA), has also
shown significant benefits. Secondary endpoint
data for etanercept (PRESTA trial) demonstrate a
significant decrease in enthesitis (-66.0%, week
12; -75.0%, week 24) and dactylitis (-74.3%,
week 12; -82.2%, week 24) [37]. However, it is
worth noting that the PRESTA trial did not
include a placebo arm.
The ADEPT trial reported efficacy of
adalimumab on enthesitis and dactylitis as
secondary endpoints [10]. Whilst the mean
changes were greater in the treatment group
over placebo [10] and these responses were
maintained throughout 2 years of therapy [38],
these changes were not statistically significant
at any time point [10, 38].
These seven trials also include data for the
anti-IL-12/23 agent ustekinumab [32], although
this is only licensed at present for the treatment
of psoriasis (PsO). Of these studies, they have all
used different outcome measures, with only a
proportion of patients having documented
baseline dactylitis or enthesitis. However,
research aside, it is seemingly evident from
clinical experience that enthesitis and dactylitis
respond well to TNF inhibitors, irrespective of
the agent employed. Early intervention to
prevent progressive joint destruction, pain and
disability has been widely embraced in the
treatment of RA [39, 40], and there is scope to
adopt such an approach in early PsA, especially
in patients who require a biologic agent for
their skin disease.
The efficacy of TNF inhibitors in preventing
bone destruction in PsA appears to be
independent of the need for combination with
DMARDs. This is not true for RA, where anti-
TNF monotherapy does not provide the same
benefit [40–46]. Often, a DMARD agent is
required in addition to a TNF inhibitor if any
attempt is to be made at ceasing joint erosion in
RA. It is unclear whether the tendency to
erosion repair seen in PsA treated with anti-
TNF monotherapy is reflective of a distinct
disease process that is intrinsically sensitive to
the suppression of inflammation, or if it
represents a disease-associated/phenotypic
process of new bone formation, or both.
Of note, while anti-TNF monotherapy may
be efficacious in PsA, patients are still prone to
a subsequent reduction in efficacy or frank
treatment failure after a period of time [47].
From studies of TNF inhibitors in RA and
inflammatory bowel disease (IBD), in addition
to improving initial therapeutic efficacy,
concurrent administration of methotrexate
has additive benefits in that it may lessen the
propensity for neutralizing or anti-drug
antibody generation [48]. A reduction in such
antibodies can retain the efficacy of an agent
in the longer term, as a result of fewer side
effects that may necessitate withdrawal (e.g.
allergic reactions) or loss of effect through
neutralization of the monoclonal antibody.
Whether this is the case in PsA awaits further
investigation: to date, there are no data
showing superiority of TNF inhibitors in
combination with DMARD versus anti-TNF-
alpha monotherapy [10, 12, 17]. Of note, in
all of the important trials of TNF inhibitors in
PsA, methotrexate was allowed, but not
required, and approximately half of these
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patients were treated with anti-TNF
monotherapy. The data for patients receiving
and not receiving concurrent methotrexate was
comparable [49].
Of course, based on available evidence, there
are certain specific circumstances that may lead
the clinician to choose one TNF inhibitor over
another. Where a patient has severe PsO, an
agent with dual efficacy and availability should
be selected. In theory, this should immediately
exclude golimumab, which is not, as yet,
licensed in the treatment of PsO. However,
where it is used primarily for PsA, in our
experience, a substantial and meaningful
improvement in PASI is repeatedly seen, and it
our experience that many rheumatologists are
confident in prescribing golimumab where
treatment for skin disease is a priority in
addition to PsA.
It has repeatedly been shown that
infliximab has superior outcomes over
etanercept and adalimumab in terms of joint,
functional status and rapid skin clearance [50]
although for this very reason, it is often not
chosen first line and is typically reserved for
more recalcitrant and severe PsO (PASI [20). In
addition, infliximab is often used second line
as a consequence of its less convenient
mode of administration (hospital-based
infusion). Of adalimumab and etanercept, the
data attempting to demonstrate which is
superior for skin and joint disease is
conflicting, and is rarely statistically
significant [50]. As mentioned previously,
there are data to suggest that etanercept may
be slower to act [9], and thus adalimumab may
be the most logical first-line choice of TNF-
alpha inhibitor for patients requiring treatment
for both PsO and PsA. However, over a
prolonged treatment course (as the majority
of patients will need), there are no robust data
to refute that etanercept will reach equivalence
with adalimumab in terms of achieving PASI
75, PASI 90 and ACR 20 [26]; therefore the
urgency to achieve these responses should be
tailored to the individual.
There is a greater body of evidence to show
that etanercept is not efficacious in those with
IBD, both in the induction and maintenance of
remission [51, 52] and it no longer features in
the most current Cochrane Systematic Review
(2008), which does support the use of
infliximab, adalimumab, and certolizumab
[53]. As the latter is not currently licensed for
use in PsA, either adalimumab or infliximab are
recommended as treatment for patients with
both IBD and PsA. From a practicality
perspective, adalimumab may be more
convenient, being self-administered at home.
WHAT TO DO WHEN TNF-
INHIBITION FAILS
The real world use of anti-TNF agents is
associated with good drug retention in the
short term. Large scale data from the Danish
DANBIO registry showed that increased levels of
C-reactive protein (CRP) at baseline were
associated with both good treatment responses
and can serve as a predictor of longer term drug
retention [25]. This may be of clinical value in
selecting cases with a greater burden of
inflammation, which are most likely to benefit
from treatment with TNF-alpha inhibitors.
TNF-inhibition irrevocably provides a
powerful clinical benefit in terms of the signs
and symptoms of PsA and can halt the
progression of erosion at a population level in
the small joints [54]. However, there is a paucity
of evidence to confirm that these agents retard
the progressive, structural changes seen in PsA
and the subsequent joint fusion that occurs
most perceptibly in the axial skeleton; this
suggests that pathways involving cytokines
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other than TNF are crucial in new bone
formation.
Whilst the investigation of many non-anti-
TNF molecules often includes patients who
have failed TNF-inhibition, it is worth noting
that to date, there are no published, completed,
randomized controlled trials in PsA that solely
include these patients. As such, there is an
unmet need to provide conclusive evidence for
a clear management strategy for this patient
group.
ANTI IL-12/IL-23 IN PSORIATIC
ARTHRITIS
Interleukin-23 (IL-23) receptor polymorphisms
and IL-12B (p40 IL-12 and IL-23 subunit)
polymorphisms have been reported in PsO and
PsA [55]. This has been supported by the
detection of elevated serum concentrations of
IL-23 in spondyloarthropathy patients. A recent
publication has shown that, in mice, IL-23
promotes a pathology that resembles
spondyloarthritis (including new entheseal
bone formation and aortic root inflammation)
by acting on a previously unidentified subset of
innate-like T cells that reside at the enthesis [1].
Collectively these findings provide robust
genetic and molecular evidence for the key
role of IL-23 in PsA based, entheseal driven
pathology.
Ustekinumab, an anti-IL-12/IL-23 p40
subunit human monoclonal antibody, is
licensed for the treatment of PsO, and exhibits
impressive reduction in PASI scores in the vast
majority of patients. Efficacy in PsA has been
investigated in one active crossover, phase II
placebo controlled trial of 146 patients, and
demonstrated moderate results (42% achieved
ACR20 at week 12, compared with 14% of those
receiving placebo) [32]. Whilst it should be
noted that response outcomes were lower than
those reported for TNF inhibitors, it is also
worth taking into account that many of these
patients had previously failed on the latter.
Extrapolating from the more substantial
experience of using biologics in RA, prior anti-
TNF failures are generally associated with poorer
response rates to all forms of treatment,
including different biologic agents, and thus
negative selection bias may have played a role
in this initial trial.
The results from the follow-on phase III
(PSUMMIT1) study were reported at the 2012
European League Against Rheumatism (EULAR)
Annual Congress, with similar results at a later
end point of 24 weeks (Table 1) [56]. Of
relevance, significant improvements in
enthesitis and dactylitis were reported in the
ustekinumab group. This was supported by
week 52 data from PSUMMIT1, presented later
in the year at the 2012 ACR Annual Conference
(Table 1) [57]. Further detail was provided
about the effects on enthesitis and dactylitis.
At week 24, median changes in enthesitis and
dactylitis scores were significantly higher than
those patients seen for patients receiving
placebo (Table 2; P\0.001 for all
comparisons). Improvements in enthesitis and
dactylitis scores continue through to week 52
(Table 2).
The results of a second phase III RCT
(PSUMMIT II) were also released at ACR 2012
[58]. PSUMMIT II recruited 312 patients, 180 of
whom were TNF-alpha experienced. In this
subgroup, significantly higher numbers of
patients receiving ustekinumab achieved
ACR20 responses at the primary endpoint
(week 24) compared with placebo (Table 1).
For all participants, including those who were
biologic naive, significantly greater proportions
achieved ACR50 at week 24 compared with
placebo, although the improvement failed to
reach significance for ACR70 (Table 1).
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The positive experience with monoclonal
antibody inhibition of the IL-12/IL-23 pathway
raised the prospect of using small orally active
molecules to attain the same feat. Successful
trials with antibodies directed against IL-12/IL-
23 in psoriatic disease, and the recent data
published into the key role of IL-23 in driving
enthesitis has supported the quest to find other
molecules that can also inhibit IL-12/IL-23
pathways. Apilimod is an orally administrated
small molecule that was developed from a novel
triazine derivative identified through high-
throughput IL-12 inhibitor screening [59]. It
selectively and potently inhibits IL-12 and IL-23
production through the inhibition of
transcription of both p35 and p40 genes and
has shown clear dose–response reduction in the
production/expression of IL-12/IL-23, the
number of infiltrating immune cells and the
clinical measures of PASI and PGA in phase I
PsO studies. However, clinically optimal drug
levels were associated with CNS-related adverse
events, preventing the molecule from
progressing to phase III trials. Similar problems
were experienced in the phase-IIa randomized
controlled trial of apilimod in patients with RA
[60]. Whilst an orally available small molecule
would provide superior convenience and cost
effectiveness, to date, no apilimod derivatives
with improved safety and pharmacokinetics
have been forthcoming to the market.
ANTI-IL-17 IN PSORIATIC ARTHRITIS
A novel cytokine target is IL-17, produced by
both innate and adaptive immune cells
including TH17 cells, which are induced by IL-
23. Currently, there are three monoclonal
antibodies that target IL-17 under
investigation—ixekizumab (formerly
LY2439821), secukinumab (formerly AIN457),
and brodalumab (formerly AMG827). Initial
Table 1 Signiﬁcant endpoint data from PSUMMIT I and PSUMMIT II















Primary endpoint (24 weeks) 42.4 49.5 22.8 24.9 27.9 8.7 12.2 14.2 2.3
Secondary endpoint (52 weeks) 55.7 60.3 No placebo 31.4 37.0 No placebo 18.0 21.2 No placebo
PSUMMIT II
Primary endpoint (24 weeks) 36.7 34.5 14.5 17.5 22.9 6.7 Did not reach signiﬁcance
Percentages reaching ACR 20, 50, and 70 after treatment with ustekinumab (UST) 45, 90 mg, or placebo [56–58]
ACR American College of Rheumatology
Table 2 Median percentage change in enthesitis and dactylitis scores after treatment with ustekinumab (UST) 45 or 90 mg
for 24 and 52 weeks [56]
PSUMMIT I Enthesitis (median % change in scores) Dactylitis (median % change in scores)
UST 45 mg UST 90 mg UST 45 mg UST 90 mg
Primary endpoint (24 weeks) -42.9 -50.0 -75.0 -70.8
Secondary endpoint (52 weeks) -83.3 -74.2 -100 -100
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investigation has focused primarily on the
dermatological manifestations of psoriatic
disease.
Of the many members of the IL-17 cytokine
family, both IL-17A and IL-17F are expressed at
elevated levels in psoriatic skin [61]. They bind
as homodimers or heterodimers to the IL-17
receptor (IL-17R), a heterodimer of IL-17RA
and IL-17RC subunits. IL-17RA is highly
expressed on keratinocytes and in psoriatic
skin—improvements induced by anti-IL-17A
therapies further supports the hypothesis that
IL-17 is a co-conspirator alongside many other
cytokines in the pathogenesis of PsO.
Brodalumab is a human IgG2 monoclonal
antibody which prevents binding and
biological activity of multiple members of the
IL-17 cytokine family (IL-17A, IL-17C, IL-17E,
IL-17A/F, IL-17F) though high affinity binding
and antagonism of the IL-17RA receptor, and
in both the phase I and II studies has
demonstrated rapid, dose-dependent
improvement in PASI scores. Further larger
scale studies are required to confirm this effect.
Ixekizumab is a humanized IgG4-type
monoclonal antibody that rapidly neutralizes
IL-17, leading to improvements both in
clinical measures of disease and
histopathologic features in lesional skin (i.e.
reduced acanthosis, hyperkeratosis and dermal
lymphocytic infiltration). These changes are
associated with a significant down-modulation
of a broad array of genes in the skin from
multiple inflammatory pathways. Similar
changes were demonstrated in a trial exploring
the efficacy of another monoclonal antibody—
secukinumab—directed against IL-17, and
reductions in PASI score were observed after
just one dose [62]. Secukinumab differs
structurally from ixekizumab in that it is a
fully human monoclonal antibody of IgG1
kappa isotype.
In addition to efficacy in PsO, ixekizumab
[63] and secukinumab [62] have demonstrated
some worth in the management of RA. Efficacy
in inflammatory disorders other than PsO is to
be expected, as IL-17 acts as an effector cytokine
much like TNF-alpha, and virtually all cell types
have been demonstrated to have a biologic
response to IL-17. IL-17 can synergize with
other pro-inflammatory cytokines to stimulate
release of additional pro-inflammatory
cytokines and chemokines, nitric oxide, and
matrix metalloproteinases. Larger scale clinical
trials are required to ascertain the safety and
efficacy profile not only in RA but also in many
other inflammatory and autoimmune diseases.
To date, only one small proof-of-concept
study has investigated IL-17A as a target for the
treatment of PsA. McInnes et al. [64]
randomized 42 patients to two injections of
secukinumab (given at 3-week intervals) or
placebo (2:1 randomization). The trial failed to
meet the primary endpoint of ACR20 at week 6
(39% active group vs. 23% placebo). At week 28,
the ACR20 response rate in the active treatment
arm was 43%, suggesting that the week 6
response rate was maintained at 28 weeks.
Again, it is worth noting that many of the
participants had previously failed TNF-
inhibition therapy, which may prejudice the
outcome. Coupled with the brief treatment
course, no firm conclusions can be made from
these data about the true efficacy of
secukinumab in PsA. Interestingly, post hoc
analysis of data from a more recent phase II
study of secukinumab in PsA by the same
authors demonstrated a week 6 ACR20
response of 10% in those previously exposed
to TNF inhibitors, compared to 62% in those
who were biologic naı¨ve [65]. Whilst the
numbers in the latter study were small, it will
be interesting to see if this observation is
repeated in larger cohorts. Overall, the
68 Biol Ther (2013) 3:61–81
123
proportion of patients in these studies
demonstrating sustained improvements in
clinical scores are encouraging and these
support the rationale for larger clinical trials of





Alefacept was the first US Food and Drug
Administration (FDA) sanctioned biologic
agent for PsO in 2003 [66]. Alefacept is a
human fusion protein with a dual mechanism
of action—firstly, it inhibits T-cell activation by
binding CD2 on T cells and thus inhibiting
leukocyte function antigen-3/CD2 interaction
with antigen-presenting cells [67]. Secondly,
alefacept also bridges between CD2 on target
lymphocytes and immunoglobulin Fc receptors
on natural killer cells. CD2 expression is higher
on memory effector than naive T cells. By
binding CD2 on memory T cells and
interacting with CD16 receptors on natural
killer cells and macrophages, alefacept induces
selective apoptosis of CD4 memory effector
cells, whilst largely sparing naive T cells [67].
However, the former action necessitates close
monitoring of the CD4 count to ensure that it
does not drop below 250 cells/mm3.
Whilst demonstrating efficacy in moderate-
to-severe PsO, alefacept was rapidly superseded
by the TNF inhibitors. However, as for most
biologics, no randomized controlled trials have
directly compared the efficacy of alefacept with
the other agents. In 2008, Brimhall et al. [68]
performed a quantitative meta-analysis of
available randomized controlled trials of four
biologic agents: alefacept, efalizumab (now
withdrawn), etanercept, and infliximab. Across
all trials, efficacy was measured by achievement
of PASI 75 after 10–14 weeks of treatment—the
study showed that all agents were efficacious for
improving PsO, though alefacept was the least
effective of the agents studied [68]. Pooled
relative risk of achieving PASI 75 was 4, 7, 12,
and 19 for alefacept, efalizumab, etanercept,
and infliximab, respectively, compared with
placebo. The corresponding numbers needed
to treat were 8, 4, 3, and 2. Alefacept is also
slower to act than TNF inhibitors for most PsO
patients [68].
Two studies have assessed the role of
alefacept in PsA [33, 69]. In the first, 185
patients were randomized 2:1 to receive either
15 mg intramuscular (IM) alefacept with
methotrexate (MTX) or placebo and MTX
weekly for 12 weeks. ACR20 response at week
24 was 54% for alefacept ? MTX versus 23% for
placebo ? MTX [33]. Response rates did not
differ according to the duration of prior
treatment with MTX.
In the second study, 185 patients with
active PsA despite at least 3 months treatment
with MTX were similarly randomized to
concurrently receive at least eight once-weekly
injections of 15 mg IM alefacept or placebo
(double-blinded), followed by a 12-week
observational period; 54% achieved ACR20
with alefacept ? MTX at week 24, versus 23%
of placebo ? MTX [69]. All eligible participants
(160 in total) were then entered into an
extension phase and received open-label
treatment with alefacept (15 mg IM
weekly) ? MTX for 12 weeks. At week 24 of the
extension phase, ACR20 reached 55% and 51%
for the two initial groups, respectively. Amongst
patients who received alefacept plus MTX in
both phases of the study, the proportion
achieving ACR50 increased with the additional
course of alefacept from 17% to 34%, and
achieving ACR70 from 7% to 12% [69].
Biol Ther (2013) 3:61–81 69
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Whilst these trials have demonstrated some
efficacy in PsA and a favorable safety profile, the
emergence of more efficacious molecules means
that alefacept is now unlikely to gain a
dominant status in the hierarchical
management of PsA.
CD28 Receptor Inhibitors
Full antigen-induced activation of naı¨ve T cells
requires two discrete signals from the antigen-
presenting cell. Antigen is presented to the
T-cell receptor in the context of a major
histocompatibility complex molecule, but full
activation occurs only when the binding of
CD80 or CD86 to the CD28 molecule on the T
cell produces a secondary co-stimulatory signal.
After activation, the T cell expresses CTLA-4,
which competes with CD28 for binding to
CD80 or CD86, leading to homeostatic down-
modulation of activated T cells.
Abatacept is a recombinant, fully human
fusion protein that consists of the extracellular
domain of CTLA-4, linked to a modified Fc
potion of human IgG1. It selectively binds to
the CD80 or CD86 receptor on the antigen-
presenting cell, blocking the second signal
T-cell activation of the CD28 receptor and
thus decreases serum levels of cytokines and
proteins implicated in the pathogenesis of
psoriatic and other inflammatory diseases [70].
Administered by monthly infusion, abatacept is
licensed in Europe and the United States for the
treatment of RA in adult patients with an
inadequate response to DMARDs or TNF
inhibitors. In 2010, it was also approved in
Europe for moderate-to-severe juvenile
idiopathic arthritis in children aged 6 and over.
A phase I trial has shown good clinical
efficacy for abatacept in PsO, with a reduction
in intralesional T-cell populations [71]. These
observations of abatacept in PsO and other
inflammatory arthritides spurred the
development of trials in PsA. Initial case
reports in PsA of two patients who previously
failed TNF inhibitors described significant
improvement in clinical signs and symptoms
of PsA after regular treatment with abatacept
[72, 73]. Formal investigation by Mease et al.
[70, 74] confirmed a significant ACR20 response
in patients randomized to 10 mg/kg abatacept
compared to placebo (48% vs. 19%, P = 0.006),
but no significant difference in those treated
with 3 mg/kg abatacept. Magnetic resonance
image assessment of synovitis and psoriatic
target lesion scores also improved with
abatacept. Unfortunately, TNF failures did not
respond as well as others in the trial (ACR20
31% vs. 56%), as seen in many studies of
alternative biologics following TNF failure.
Because abatacept was the first therapy
targeting the inhibition of co-stimulatory
signals to prevent T-cell activation, its use in
early disease [75] and in biologic-naı¨ve patients
with active RA [76, 77] has generated particular
interest and investigation [78–81]. These data
may support the investigation of abatacept in
biologic-naı¨ve patients with early inflammatory
joint disease who have had an inadequate
response to MTX. However, it is worth noting
that patients included in these studies were
exposed to concomitant corticosteroids [76, 77].
SMALL MOLECULES IN PSORIATIC
ARTHRITIS
In contrast to biologics, which target soluble
extracellular cytokine or cellular receptors,
small molecule inhibitors target intracellular
enzymes within a signaling pathway, e.g.,
tyrosine kinases. In essence, this can make it
more difficult to anticipate their complete
biological effects and may cause potential for
unintended side effects, as these molecules will
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often interact with the same enzymes but in
non-targeted cells involved other biological
processes. However, if this can be overcome,
small molecule inhibitors have several
advantages over biologic agents in that they
can be administered orally, and as synthetic
compounds, they are comparatively
inexpensive to manufacture.
Protein Kinase C Inhibitors
The protein kinase C (PKC) family consists of 10
isoenzymes and each play key roles in cellular
signaling, migration, survival and death [82].
Most isoforms are ubiquitously expressed,
except PKCc and PKCh. PKCc is exclusively
found within the brain, whilst high protein
levels of PKCh are seen mostly in hematopoietic
cells and skeletal muscle [83].
PKCh (along with PKCb and PKCd) are
functionally important for T and B cell
signaling [83, 84]. PKCh is central to T-cell
activation as it is the only isoenzyme that is
selectively translocated to the T-cell/antigen-
presenting cell contact site immediately after
cell-to-cell interaction [85]. Furthermore, PKCh
is essential for IL-2 production, which is
required for T-cell proliferation. PKCa in T
cells is required for proliferation [86], in
addition to IFNc and IL-17 production. PKCb
is a prerequisite for B cell antigen receptor
function, and PKCd for the induction of
tolerance [87]. Identification of specific PKC
isoenzymes in T and B cells has promoted their
attractiveness as therapeutic targets for
inflammatory and autoimmune diseases [88].
To date, only one PKC inhibitor—
sotrastaurin (AEB071)—is in the exploratory
phase of drug development for autoimmune
diseases [89]. Sotrastaurin has a strong
inhibitory activity on three PKC isoforms—
PKCh, PKCa and PKCb, and weaker activity on
PKCd, PKCe, and PKCg, meaning that in
addition to T-cell activity, it has inhibitory
effects on several other cells [82]. It affects
more than 200 kinases, including those
important for early T-cell activation such as
Lck and ZAP-70. Phase II trial data have shown
promising efficacy in PsO and transplant
rejection [90]. The proven potent inhibition of
IL-17 by sotrastaurin makes this molecule a
potential future therapeutic target in PsA [91].
Janus Kinase Inhibitors
Another family of kinases commanding interest
in PsO are the Janus kinases (JAK), of which
there are four members—JAK1, JAK2, JAK3, and
TYK2 [92]. These enzymes, which are expressed
primarily in immune and hematopoietic cell
lineages, form part of the signaling apparatus
used by receptors for various cytokines and
growth factors. When such receptors are
engaged by their specific ligands, JAKs
phosphorylate and thus activate members of
the signal transducer and activator of
transcription (STAT) family [93]. There are
seven STATs (STAT 1, 2, 3, 4, 5a, 5b, and 6),
each with a variety of distinct effects on gene
transcription in cells of the immune system that
are critical in processes such as lymphocyte
differentiation, immune regulation and
inflammation [94].
Members of the JAK family can combine to
form homodimers or heterodimers; these
unique pairings give rise to the signaling of
specific cytokines. For example, IL-12 and IL-23
have been reported to signal through JAK2–
TYK2 heterodimers [92], thus targeting of this
pathway would be expected to produce similar
therapeutic efficacy to ustekinumab [95]. JAK
inhibitors also inhibit signaling from many
other cytokines, including IL-17 (which
activates multiple JAKs via IL-17R) [96], IL-20
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[97], IL-22 (JAK1), and IFNc (JAK1/2
heterodimers) [92]. JAK3 specifically
transduces signals from IL-2, IL-7, IL-15, and
IL-21, which are integral to lymphocyte
function and survival, and inhibition of their
signaling may result in modulation of multiple
aspects of the immune response [98]. JAK
inhibition therefore has the potential to
positively impact on many inflammatory
disorders.
Data from phase I and II studies has
established that cytokine signaling through
the JAK pathway is an important component
of the pathogenesis of both PsO and RA, and
promising efficacy has been achieved with a
compound now known as tofacitinib (CP-
690550) in both disorders [99–101]. First
described in 2003, it was initially described as
a JAK3 inhibitor that could prevent allograft
rejection [102]. However, it is now considered
to powerfully inhibit both JAK1 and JAK3
(which can function as signaling
heterodimers), and to a much lesser extent,
JAK2 [103]. The reported success in phase III
trials means that it has recently been licensed
for treatment of RA in the US [100]. The
response to tofacitinib of coincidental PsO in
patients with inflammatory RA provides a
logical argument for investigation of efficacy
in PsA, and is likely that trial data will soon
become available in this domain.
Therapeutic inhibition of more selective JAK
inhibitors is under investigation. The most
extensively studied is ruxolitinib (INCB28050),
a selective JAK1/JAK2 inhibitor that has been
investigated primarily in myelofibrosis. Latterly,
a topical preparation of ruxolitinib has been
developed for use in the treatment of PsO, and
in a phase-IIb proof-of-concept study of 29
patients, has been reported to improve mean
total lesion scores (approximately 53%
reduction) and PGA at the 1 and 1.5%
concentrations after 28 days of continuous use
[93, 104]. However, no firm conclusions can be
drawn from this small study, and the high
placebo response rate (32% reduction in mean
total lesion scores) may simply reflect improved
compliance with a topical regimen during the
trial.
In terms of inflammatory arthritis,
significant efficacy (as assessed by
improvements in clinical, histologic, and
radiographic signs of disease), has been
achieved in the rat adjuvant arthritis model,
with doses of ruxolitinib providing partial and/
or periodic inhibition of JAK1/JAK2 and no
inhibition of JAK3 [105]. Diminution of
inflammatory Th1 and Th17 associated
cytokine mRNA levels were observed in the
draining lymph nodes of treated rats.
Ruxolitinib was also effective in multiple
murine models of arthritis, with no evidence
of suppression of humoral immunity or adverse
hematological effects [105]. As a result, clinical
evaluation of ruxolitinib for RA is currently
underway in humans.
Another orally active small molecule
undergoing extensive investigation in a
number of inflammatory disorders is ASP015K.
This molecule selectively targets JAK1/JAK3 and
in a 6-week phase-IIa POC study of patients
with PsO, ASP015K was well tolerated and
demonstrated dose-dependent improvements
in PASI change from baseline [106]. ASP015K
is currently being investigated in three phase-
IIb studies in patients with RA in the United
States, Europe and Japan, with no efficacy data
released to date.
A more selective small molecule—
CEP33779—which selectively targets only
JAK2, has shown efficacy in two mouse models
of RA by inhibiting the transduction of signals
for several essential pro-inflammatory
cytokines, including IL-6, IFNc, and IL-12
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[107]. It has been proposed that use of a
selective, rather than pan-JAK inhibitor,
avoids the potential complications of
immunosuppression, whilst targeting critical
signaling pathways involved in autoimmune
disease progression. Further safety data are
needed on all agents before this conclusion
can be definitively drawn.
Phosphodiesterase Inhibitors
Phosphodiesterase-4 plays a key role in
degrading cyclic-AMP in cells—inhibition leads
to diminished T-cell secretion of pro-
inflammatory cytokines, including TNF-alpha,
IFN-c, PDE-4, nitric oxide synthase, IL-2, IL-17,
and IL-23 and blocks the degradation of cAMP.
Apremilast, a phosphodiesterase-4 inhibitor, is
currently in phase III trials in PsO, AS, and
PsA. Positive results have been reported in PsO;
in one phase-IIb, double-blind, four-arm,
randomized controlled study, 352 patients
received either 30 mg, 20 mg, or 10 mg oral
apremilast twice daily or placebo with 41% of
the active treatment group achieving PASI 75
compared to just 6% in the placebo arm [108].
In a similar phase II study of 204 patients
with PsA, a modest but significant improvement
in ACR20 was achieved at both 20 mg twice
daily and 40 mg once daily doses. A significant
difference was not seen in ACR70, with very few
patients achieving such a marked improvement
in disease activity [109]. Preliminary phase III
data for apremilast from the PALACE 1
(Psoriatic Arthritis Long-Term Assessment of
Clinical Efficacy) study in active PsA was
recently presented at the 2012 ACR annual
meeting. A primary endpoint of ACR20 at week
16 was achieved in 31.3% (P = 0.0140) of
patients receiving apremilast 20 mg twice daily
and 41.0% (P\0.0001) receiving apremilast
30 mg twice daily compared with 19.4%
patients receiving placebo. Adverse events
included gastrointestinal upset, headache, and
upper respiratory tract infections. Most were
mild or moderate in severity and necessitated
study discontinuation in up to 7%.
TNF Antagonist Gene Therapy
A recombinant adeno-associated virus (rAAV)
serotype 2-based vector containing human TNF-
immunoglobulin (IgG1) Fc fusion gene (rAAV-
TNFR:Fc) has been developed for clinical use
[110]. Once injected into the affected joint(s),
the DNA coding for a therapeutic protein is
incorporated into native tissue cells by the
process of gene transfer. The use of a vector is
required to facilitate uptake of the single-
stranded DNA by cells within the joint and
incorporate it into the genome. Subsequent
transcription/translocation should then
provide sustained concentrations of the
therapeutic protein within the joint [110].
rAAV-TNFR:Fc is based on an adeno-associated
virus—a naturally occurring, non-pathogenic,
non-integrating and non-replicating virus that
depends on a helper virus for replication [111].
To date, one phase I/II study of patients
with inflammatory arthritis (including PsA)
treated with rAAV-TNFR:Fc has been
published [112]—127 patients were
randomized to receive intra-articular
injections of escalating dose concentrations of
the gene, or placebo (3:1 randomization) into a
single target joint. Injection site reactions
occurred in 20% and were dose-related. Septic
arthritis developed in one patient 15 weeks
after administration of rAAV-TNFR:Fc, which
was deemed ‘probably related’ to the gene
therapy, due to the increased risk of infection
caused by expression of TNFR:Fc protein in the
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joint. In terms of efficacy, patient reported
outcome measures (global visual analogue
scores) yielded a greater difference between
drug and placebo than clinical examination for
the target joint, but this was not statistically
significant [112].
Other Molecules in Phase I/II Studies
Several novel agents are in phase I and II trials
for a number of inflammatory/immune cell
driven disorders, including PsO and RA. Based
on experience, for some, it is likely that the
natural evolution of investigation for many of
these agents will extend to PsA, whilst safety
concerns and disappointing efficacy data may
halt the progression of others into the clinical
domain. Table 3 lists the new compounds
currently in early clinical trials in psoriatic
disease and other inflammatory arthritides
that have not been discussed elsewhere in this
paper.
CONCLUSION
The advent of biologic therapies has
revolutionized the treatment of PsA and
facilitated a real, meaningful, and measurable
reduction in both disease progression and
symptomatology. With more than a decade of
safety data for TNF-alpha inhibitors, confidence
in the use of biologics is increasing, and the net
is being cast ever wider in the search for new
biomarkers, molecular pathways, and
therapeutic targets.
The impressive efficacy of TNF inhibitors in
inflammatory disease has led to a significantly
greater understanding of the inflammatory
cascade and allowed for the identification of
more direct molecular targets. Numerous
agents, both biological and non-biological are
in development which can precisely modulate
or inhibit key molecules in the pathogenesis of
inflammatory arthritis, and are showing
promising results in phase II/III trials. The
relative efficacy of these agents remains to be
established, and, in time, head-to-head trials
will be required to determine the best treatment
options for patients.
The prospect of preventing radiographic
damage in RA and PsA has led to a re-
evaluation of how patients with inflammatory
arthritides are managed—attempts are being
made to identify specific phenotypic
subgroups of patients who are more likely to
derive benefit from selected treatments. Not
only will this hasten the attainment of
symptomatic relief, but could potentially
reduce the economic burden imposed by ‘trial
and error’ therapeutics and significantly lessen
the physical and psychosocial morbidity of
chronic disease.
The exciting search for the ultimate
inhibitor of musculoskeletal inflammation
continues, in terms of superior efficacy,
safety, tolerability, mode of administration,
and the ability to specifically target aberrant,
pathogenic inflammatory pathways in multiple
organ systems, without causing damage to
healthy structures. Psoriatic disease is an ideal
disease model, where aberrations in common
inflammatory pathways give rise to the
musculoskeletal, cutaneous and/or systemic
phenotype, and is anticipated that in future,
treatment options may become tailored to an
individual’s clinical phenotype with the aid of
imaging, serological and genetic biomarkers.
The key challenge facing rheumatologists will
then be how best to integrate all of the new,
targeted molecules into daily practice,
although the increasing armamentarium at
their disposal will allow the provision of a
significantly improved quality of life for many
more patients.
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Table 3 Molecules in development for psoriasis and rheumatoid arthritis
Compound Disease Mechanism Type Company
AbGn-168 Psoriasis Biologic Anti-P-selectin glycoprotein
ligand (PSGL)-1
Boehringer Ingelheim





Biologic Anti-IL23 p19 Janssen-Cilag
SCH900222 Psoriasis Biologic Anti-IL23 p19 Sanoﬁ Pasteur MSD
ACT-128800 Psoriasis Small molecule inhibitor Sphingosine-1-phosphate
(S1P) agonist
Actellion
VB-201 Psoriasis Small molecule inhibitor Immune modiﬁer VBL Therapeutics
APG2305 Psoriasis Small molecule inhibitor Anti-IL-23R Allostera Pharma
Erlotinib Psoriasis Small molecule inhibitor Anti-eGFR OSI Pharmaceuticals
RWJ-445380 Psoriasis Small molecule inhibitor Cathepsin S inhibitor Johnson & Johnson
R3421 (BCX-4208) Psoriasis Small molecule inhibitor Purine nucleoside
phosphorylase inhibitor
Roche/BioCryst
CF101 Psoriasis Small molecule inhibitor Adenosine receptor agonist Can-Fite BioPharma
BMS582949 Psoriasis and
RA
Small molecule inhibitor P38 inhibitor Bristol-Myers Squibb
Fostamatinib Psoriasis and
RA
Small molecule inhibitor Spleen tyrosine kinase
(SYK) inhibitor
Astra-Zeneca/Rigel




GLPG0634 RA Small molecule inhibitor JAK-1 inhibitor Galapagos
CCX354-C RA Small molecule inhibitor Chemokine receptor-1
(CCR1) antagonist
ChemoCentryx
CCX168 RA Small molecule inhibitor Complement (C5a)
receptor antagonist
ChemoCentryx
VX-509 RA Small molecule inhibitor JAK-3 inhibitor Vertex
Baricitinib
(INCB028050)
RA Small molecule inhibitor JAK1/2 inhibitor Eli Lilly/InCyte
LX3305 (LX2931) RA Small molecule inhibitor Sphingosine-1-phosphate
(S1P) lyase inhibitor
Lexicon
VX-702 RA Small molecule inhibitor P38 MAPK Vertex
Tasocitinib
(CP-690550)
RA Small molecule inhibitor JAK-3 inhibitor Pﬁzer
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